The truth is out there: An overall perspective on androgen deprivation

Beth A. Hellerstedt, Kenneth J. Pienta

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Androgen deprivation therapy (ADT) is a mainstay in the treatment of prostate cancer. The ideal timing, duration and composition of ADT remains undefined. At the present time, first-line therapy consists of orchiectomy, LHRH agonists, or combined androgen blockade (CAB). However, new combinations and treatment settings show promise for improving outcomes and decreasing toxicity.

Original languageEnglish (US)
Pages (from-to)272-281
Number of pages10
JournalUrologic Oncology: Seminars and Original Investigations
Issue number4
StatePublished - Jul 2003
Externally publishedYes


  • ADT
  • Adjuvant
  • Cost
  • LHRH agonist
  • Neoadjuvant

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'The truth is out there: An overall perspective on androgen deprivation'. Together they form a unique fingerprint.

Cite this